Patients enrolled in the Speckle Tracking Assisted Resynchronization Therapy for Electrode Region ( STARTER ) prospective , randomized trial who were treated with a CRT-D device ( 108 EG strategy and 75 routine strategy ) were followed to the end-points of death , appropriate CRT-D therapy , or HF hospitalization .